Treatment of Hepatitis C Vere CC et al. tis C RNA titers during routine clinical use? World J Gastroenterol. 2009;15(40):5020-7. 5. Ye J, Wang C, Sumpter R, Jr., Brown MS, Goldstein JL, Gale M, Jr. Disruption of hepatitis C virus RNA replication through inhibi- tion of host protein geranylgeranylation. Proc Natl Acad Sci U S A. 2003;100(26):15865-70. 6. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regu- lated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A. 2005;102(7):2561-6. 7. Gibson K, Rindone JP. Experience with statin use in patients with chronic hepatitis C infection. Am J Cardiol. 2005;96(9):1278-9. 8. Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepa- totoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol. 2006;4(7):902-7; quiz 806. 9. Segarra-Newnham M, Parra D, Martin-Cooper EM. Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus. Pharmacotherapy. 2007;27(6):845-51. 10. Delang L, Paeshuyse J, Vliegen I, Leyssen P, Obeid S, Durantel D, et al. Statins potentiate the in vitro anti-hepatitis C virus activ- ity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology. 2009;50(1):6-16. 11. Harrison SA, Rossaro L, Hu KQ , Patel K, Tillmann H, Dhaliwal S, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology. 2010;52(3):864-74. 12. Bader T, Fazili J, Madhoun M, Aston C, Hughes D, Rizvi S, et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gas- troenterol. 2008;103(6):1383-9. 13. O’Leary JG, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology. 2007;45(4):895-8. 14. Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, et al. Characterization of low- and very-low- density hepatitis C virus RNA-containing particles. J Virol. 2002;76(14):6919-28. 15. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low- density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol. 2006;80(5):2418-28. 16. Nahmias Y, Goldwasser J, Casali M, van Poll D, Wakita T, Chung RT, et al. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology. 2008;47(5):1437-45. 17. Corouge M, Pol S. New treatments for chronic hepatitis C virus infection. Med Mal Infect. 2011;41(11):579-87. 18. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayas- hi N. Telaprevir with peginterferon and ribavirin for treatment- naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56(1):78-84. 19. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infec- tion. N Engl J Med. 2011;364(13):1195-206. 20. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-17. Hepat Mon. 2012:12(6) 371